Outlook Therapeutics (OTLK) announced that LYTENAVA is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration. LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK. Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe and the United States for the treatment of retinal diseases. ONS-5010/LYTENAVA has potential to mitigate certain risks associated with the current off-label use of repackaged bevacizumab. Outlook Therapeutics has entered into a strategic collaboration with Cencora to support the commercial launch of LYTENAVA globally following regulatory approvals. The collaboration and integrated approach is designed to support market access and efficient distribution of LYTENAVA to benefit all stakeholders, including retina specialists, providers and patients in certain European markets and, if approved, in the United States.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Announces New Stock and Warrant Offering
- Outlook Therapeutics 9.3M share Spot Secondary priced at $1.40
- Outlook Therapeutics Reports Improved Financials Amid Challenges
- Outlook Therapeutics announces common stock, warrants offering
- Outlook Therapeutics price target lowered to $8 from $10 at Guggenheim